Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SMAD family member 3 (SMAD3)
- Target
- SMAD3
- Molecular classification
- Transcription factor, Signal transducer (Receptor-regulated SMAD, R-SMAD), Intracellular signaling molecule
01
Overview
SMAD family member 3 (SMAD3) is an intracellular signal transducer and transcriptional modulator that plays a central role in the transforming growth factor-beta (TGF-beta) signaling pathway. Upon activation by TGF-beta receptors—membrane serine/threonine kinases—SMAD3 becomes phosphorylated along with other receptor-regulated SMADS such as SMAD2. The activated complex then translocates to the nucleus where it regulates target gene expression involved in diverse cellular processes including proliferation, apoptosis, migration, differentiation, extracellular matrix production, immune regulation, and development. Dysregulation of this protein’s function has been implicated in various pathological conditions such as cancer progression/tumorigenesis and connective tissue disorders like Loeys-Dietz syndrome type III.
- Other names
- Mothers against decapentaplegic homolog 3MAD homolog 3JV15-2hSMAD3
02
Mechanism of action
Drugs or molecules that modulate the TGF-beta pathway can inhibit or enhance phosphorylation and activation of SMAD3, thereby altering downstream gene transcription involved in cell proliferation, apoptosis, and differentiation.
03
Biological functions
Signal transduction (TGF-beta/transforming growth factor-beta pathway)Regulation of gene expressionCell proliferationApoptosis (programmed cell death)Cell migrationBifferentiation
04
Disease associations
Cancer (tumor growth and progression)Connective tissue disorders (e.g., Loeys-Dietz syndrome type III)Fibrosis
05
Safety considerations
Therapeutic modulation of the TGF-beta/SMAD pathway can lead to broad effects on cell growth, immune response, fibrosis, and tissue homeostasis.Inhibition may risk impaired wound healing or immune dysregulation; overactivation is linked to fibrosis and cancer progression.
06
Interacting drugs
No specific drugs directly targeting SMAD3 are widely approved or in clinical use as of now. However, some experimental compounds and TGF-beta pathway inhibitors may indirectly affect its activity.
07
Biomarkers
Mutations in the SMAD3 gene serve as biomarkers for Loeys-Dietz syndrome type III.Altered expression or activity may also be explored as a biomarker for certain cancers and fibrotic diseases
Beyond the preview
Go deeper on SMAD family member 3 (SMAD3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SMAD family member 3 (SMAD3).